share_log

Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder

Benzinga Real-time News ·  Jan 31, 2023 07:42
Reneo Pharmaceuticals Receives Fast Track Designation From FDA For Mavodelpar In A Genotype Af Long-Chain Fatty Acid Oxidation Disorder
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment